Healthspan vs Lifespan: The 12.4-Year Gap Nobody Can Sell You

Two numbers, and only one of them is advertised

Every conversation about living longer quietly conflates two measurements that behave quite differently. The first is lifespan: how many years you are alive. The second is healthspan, formalised by the World Health Organization as health-adjusted life expectancy — the number of years lived without significant disease or disability.

Subtract one from the other and you are left with a figure that almost nobody in the longevity trade puts on a brochure. It is the stretch of life spent managing rather than living: the years of medication schedules, reduced mobility, cognitive narrowing, and dependence. The literature calls it the healthspan–lifespan gap, or more bluntly, the morbidity gap.

It is, we would argue, the only longevity statistic that deserves a reader's full attention. A number that rises while the thing it measures gets worse is the signature of a problem that money alone has not solved.

The 12.4 years that belong to America

In December 2024, Andre Terzic and Armin Garmany at the Mayo Clinic did the arithmetic across every WHO member state — 183 nations, two decades of follow-up — and published it in JAMA Network Open.^[1] The global gap had widened to 9.6 years.

The finding that travelled was national. The country with the largest healthspan–lifespan gap on earth was the United States, at 12.4 years, driven by a rise in non-communicable disease. The nation that spends the most per capita on healthcare, and which hosts essentially the entire commercial longevity industry, has engineered for itself the longest period of unwell living of any country measured.

That is not a failure of spending. It is a failure of what the spending is pointed at. A system superb at preventing death from a heart attack, and comparatively indifferent to the decade of diminished life that follows one, will produce exactly this number.

The gap is not closing. It is opening.

The most recent and most rigorous accounting arrived in August 2026, when the Global Burden of Disease 2023 collaborators published a full morbidity-gap analysis in The Lancet Public Health.^[2] It is worth reading the two columns side by side.

Within a single generation, humanity added more than nine years of life and just over seven years of health. The surplus — roughly two years per person, globally — went into the gap. As the authors put it, we are adding years to life faster than we are adding health to those years.

The widening was observed across the whole adult lifespan rather than only at the very end, which rules out the comforting interpretation that this is simply more people reaching very old age. It is not only that more of us arrive at eighty. It is that more of the road there is spent unwell.

Fries was not wrong. He was early, and possibly optimistic.

In 1980 the Stanford physician James Fries proposed in the New England Journal of Medicine what became the governing hope of modern geriatrics: the compression of morbidity.^[5] If the maximum human lifespan is relatively fixed, he argued, then pushing the onset of chronic disease later and later must eventually squeeze the period of illness into a short, sharp decline at the very end. A long, vigorous life followed by a brief exit.

It is an elegant hypothesis, and for certain populations with certain behaviours it has held. At the global scale, over the four decades since, the opposite has occurred: expansion rather than compression. The onset of chronic disease has been delayed, but survival with chronic disease has been extended by considerably more. Medicine learned to postpone death from the conditions of ageing more effectively than it learned to postpone the conditions themselves.

This is the context in which every claim about the ceiling on maximum human lifespan should be read. Raising the ceiling is a different project from raising the floor, and only one of them is currently going well.

The worm that should give the industry pause

There is a result from basic biology that deserves to be far better known than it is, because it suggests the gap may not be an accident of healthcare systems at all.

In 2015 Heidi Tissenbaum's group at UMass took the four canonical longevity interventions in Caenorhabditis elegans — reduced insulin/IGF-1 signalling, dietary restriction, reduced protein translation, and altered mitochondrial signalling — and did something the field had largely neglected. Rather than counting only days survived, they measured the animals' actual function longitudinally as they aged: movement, stress resistance, muscle integrity.^[4]

Some mutants did outperform wild type in absolute terms. But the headline finding was uncomfortable for everyone involved: all four long-lived mutants increased the proportion of life spent in a frail state. The interventions extended life, and extended the frail portion of it by more. In the organism where lifespan extension is most reliably achieved, healthspan did not follow automatically.

No one should over-read a nematode. Worms are not people, and the translation of any worm result to human biology has a poor historical record. But it undercuts a load-bearing assumption — that anything which lengthens life must also lengthen health — and it does so in precisely the model systems that generated the enthusiasm for rapamycin and dietary restriction in the first place. The assumption needs evidence, not inheritance.

Geography: the gap is universal, its shape is not

A follow-up analysis from the same Mayo group, published in Communications Medicine in September 2025, mapped the gap across six WHO regions and used unsupervised machine learning to cluster the disease patterns underneath it.^[3] Three findings matter for anyone reasoning about their own trajectory.

First, the gap is universal — present in all 183 states — but its composition differs. Three distinct global morbidity clusters emerged, meaning two countries can share an identical gap in years while the disease burden producing it looks nothing alike. The authors explicitly caution against global generalisation and against one-size solutions.

Second, the correlates were consistent: life expectancy itself, gross domestic product, and non-communicable disease burden tracked the gap most reliably. Wealth and longevity are, perversely, among the better predictors of a wide gap.

Third, Africa presents the narrowest gap of any region while simultaneously showing the greatest expansion and the most rapid restructuring of disease burden — a region moving quickly toward the pattern the wealthy world already has. Europe, by contrast, is over-represented among countries whose gaps are smaller than their wealth would predict. Projections to 2100 forecast continuous widening across every region.

The women's paradox

The sex difference is persistent and poorly explained. Women outlive men almost everywhere on earth, and in 2023 carried a morbidity gap of 12.1 years against men's 9.3.^[2] The Mayo analysis found the same direction independently: a mean gap 2.4 years wider in women, associated with a disproportionately larger burden of non-communicable disease.^[1]

The additional years women gain are therefore not equivalent currency to the years men gain. Part of the explanation is straightforwardly mechanical — surviving longer means accumulating more conditions, and the diseases women survive with, particularly musculoskeletal and mental health conditions, are disabling rather than fatal. Part of it is likely diagnostic and social rather than biological. None of it is settled, and we would treat any confident single-cause explanation with suspicion — though proteomic work published in 2026 has since supplied the first mechanistic candidate with a date attached, in the molecular signature of menopause.

What this changes for the discerning

The practical consequence of the gap is a reordering of what is worth measuring. If the years being added are disproportionately unwell years, then a longevity programme optimised for mortality risk is optimised for the wrong endpoint.

This is the strongest argument for the shift toward function and organ-level measurement that has defined the last two years of the field. A mortality estimate tells you how long the corridor is. Measures such as organ-specific proteomic ageing and inflammatory age attempt something harder and more useful: identifying which system is likely to fail first, and therefore which one determines where your own gap begins. The evidence that acting on these measures changes an individual outcome remains, as we have written elsewhere, absent.

Three honest limitations deserve stating plainly. These are population statistics, and no national average predicts an individual life. Health-adjusted life expectancy is a modelled construct built on disability weights that involve real judgement calls, so the gap figures carry uncertainty the headline numbers conceal. And the one causal question that matters most — whether any available intervention compresses an individual's personal gap — has not been answered by a controlled trial, for any intervention, in humans.

What the data does support is unglamorous and already known. The conditions that generate the gap are overwhelmingly non-communicable: cardiometabolic disease, musculoskeletal decline, and cognitive decline. Those are the targets. Preserved muscle, preserved metabolic health, preserved cognition and preserved social connection are the four levers with the deepest evidence behind them, and none of them are purchasable.

The luxury, in the end, is not the extra decade. Everyone in a wealthy country now gets some version of that. The luxury is whether you can use it.